Respiratory syncytial virus (RSV) results in 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths of adults 67 and older each year, but newly approved vaccines could make a significant public health and economic impact. In a recent study, U-M researchers evaluated the newly approved vaccines on their cost-effectiveness and efficacy. Contributor David Hutton comments on the findings for the Institute for Healthcare Policy and Innovation.
